Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aegea raises $17mm through late-stage equity round

Executive Summary

Aegea Medical Inc. (minimally invasive endometrial ablation) raised $17mm through an undisclosed late-stage equity round led by Solas BioVentures. The company will use the proceeds to fund a multi-center study to evaluate its Adaptive Vapor Ablation system in uterine cavity access (and possible minimally invasive interventions) three to four years post-treatment. Proceeds will also support the commercial launch (anticipated in 2019) of Aegea’s next-generation Adaptive Vapor Ablation, an FDA-approved endometrial ablation system for the minimally invasive treatment of menorrhagia (heavy menstrual bleeding) in a physician’s office setting. Since its 2007 inception, the company has brought in $108.5mm.
Deal Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies